PPARG and Insulin resistance: In this line, our group (2019) also determined, by studying nuclear extract from visceral adipose tissue, that the activation of IGFBP2 promoter by PPARγ2-RXRα heterodimer was decreased in 11 high insulin resistance patients with morbid obesity, when compared with in 12 low insulin resistance patients [14].